Yahoo Finance·2025-10-30 13:56Group 1 - Pfizer Inc. is considered one of the most undervalued large-cap stocks currently available for investment [1] - On October 24, Pfizer Singapore and BioNTech announced the approval of their LP.8.1-adapted monovalent COVID-19 vaccine by the Health Sciences Authority of Singapore [1][2] - Singapore is the first country in Southeast Asia to fully approve this latest COVID-19 vaccine for individuals aged 6 months and older [2][3] Group 2 - The LP.8.1 sublineage was selected based on guidance from the US FDA, EMA, and WHO, indicating it as the preferred sublineage for a monovalent JN.1-lineage-based COVID-19 vaccine in the US starting in fall 2025 [2] - The updated COVID-19 vaccine is expected to be available in Singapore at selected polyclinics and private clinics starting in October 2025 [3] - Under Singapore's National Vaccination Programme, the COVID-19 vaccine will remain free for all Singapore Citizens, Permanent Residents, Long-Term Pass Holders, and certain Short-Term Pass holders [3]